Clinical Trial Update: Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin [Phase 2]

View source ↗

Summary

Phase 2 trial update on a second-line treatment combining Envafolimab, Lenvatinib, and Paclitaxel-albumin for advanced gastric/gastroesophageal junction adenoca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Gastroesophageal Junction Adenocarcinoma

Drugs mentioned

• Envafolimab (envafolimab)
• Lenvatinib (lenvatinib)
• paclitaxel-albumin (paclitaxel-albumin)

Snippet

Sponsor: Fudan University | Conditions: Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 2 | Status: UNKNOWN